471 related articles for article (PubMed ID: 31461239)
1. A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial.
Mehra MR; Vaduganathan M; Fu M; Ferreira JP; Anker SD; Cleland JGF; Lam CSP; van Veldhuisen DJ; Byra WM; Spiro TE; Deng H; Zannad F; Greenberg B
Eur Heart J; 2019 Nov; 40(44):3593-3602. PubMed ID: 31461239
[TBL] [Abstract][Full Text] [Related]
2. Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial.
Zannad F; Greenberg B; Cleland JG; Gheorghiade M; van Veldhuisen DJ; Mehra MR; Anker SD; Byra WM; Fu M; Mills RM
Eur J Heart Fail; 2015 Jul; 17(7):735-42. PubMed ID: 25919061
[TBL] [Abstract][Full Text] [Related]
3. Natriuretic Peptide-Based Inclusion Criteria in a Heart Failure Clinical Trial: Insights From COMMANDER HF.
Cunningham JW; Ferreira JP; Deng H; Anker SD; Byra WM; Cleland JGF; Gheorghiade M; Lam CSP; La Police D; Mehra MR; Neaton JD; Spiro TE; van Veldhuisen DJ; Greenberg B; Zannad F
JACC Heart Fail; 2020 May; 8(5):359-368. PubMed ID: 32171760
[TBL] [Abstract][Full Text] [Related]
4. High Risk of Stroke in Patients With Worsening Heart Failure, Reduced Ejection Fraction, Coronary Heart Disease and Sinus Rhythm: Risk Prediction Score Analysis From the COMMANDER-HF Trial.
Monzo L; Girerd N; Ferreira JP; Lamiral Z; Anker SD; Cleland JGF; Kondo T; McMurray JJV; Lam CSP; Mehra MR; Veldhuisen DJV; Greenberg B; Zannad F
J Card Fail; 2024 Apr; 30(4):618-623. PubMed ID: 38122924
[TBL] [Abstract][Full Text] [Related]
5. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF.
Hankey GJ; Patel MR; Stevens SR; Becker RC; Breithardt G; Carolei A; Diener HC; Donnan GA; Halperin JL; Mahaffey KW; Mas JL; Massaro A; Norrving B; Nessel CC; Paolini JF; Roine RO; Singer DE; Wong L; Califf RM; Fox KA; Hacke W;
Lancet Neurol; 2012 Apr; 11(4):315-22. PubMed ID: 22402056
[TBL] [Abstract][Full Text] [Related]
6. Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: a post-hoc subanalysis of VITATOPS, a randomised, placebo-controlled trial.
Hankey GJ; Eikelboom JW; Yi Q; Lees KR; Chen C; Xavier D; Navarro JC; Ranawaka UK; Uddin W; Ricci S; Gommans J; Schmidt R;
Lancet Neurol; 2012 Jun; 11(6):512-20. PubMed ID: 22554931
[TBL] [Abstract][Full Text] [Related]
7. Major vascular events after transient ischaemic attack and minor ischaemic stroke: post hoc modelling of incidence dynamics.
Atanassova PA; Chalakova NT; Dimitrov BD
Cerebrovasc Dis; 2008; 25(3):225-33. PubMed ID: 18216464
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of patients with atrial fibrillation on oral anticoagulation with and without heart failure: the ETNA-AF-Europe registry.
Schnabel RB; Ameri P; Siller-Matula JM; Diemberger I; Gwechenberger M; Pecen L; Manu MC; Souza J; De Caterina R; Kirchhof P
Europace; 2023 Aug; 25(9):. PubMed ID: 37713182
[TBL] [Abstract][Full Text] [Related]
9. Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin.
Algra A; de Schryver EL; van Gijn J; Kappelle LJ; Koudstaal PJ
Cochrane Database Syst Rev; 2001; (4):CD001342. PubMed ID: 11687110
[TBL] [Abstract][Full Text] [Related]
10. Prediction of stroke or TIA in patients without atrial fibrillation using CHADS2 and CHA2DS2-VASc scores.
Mitchell LB; Southern DA; Galbraith D; Ghali WA; Knudtson M; Wilton SB;
Heart; 2014 Oct; 100(19):1524-30. PubMed ID: 24860007
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial.
Sharma M; Molina CA; Toyoda K; Bereczki D; Bangdiwala SI; Kasner SE; Lutsep HL; Tsivgoulis G; Ntaios G; Czlonkowska A; Shuaib A; Amarenco P; Endres M; Yoon BW; Tanne D; Toni D; Yperzeele L; von Weitzel-Mudersbach P; Sampaio Silva G; Avezum A; Dawson J; Strbian D; Tatlisumak T; Eckstein J; Ameriso SF; Weber JR; Sandset EC; Goar Pogosova N; Lavados PM; Arauz A; Gailani D; Diener HC; Bernstein RA; Cordonnier C; Kahl A; Abelian G; Donovan M; Pachai C; Li D; Hankey GJ
Lancet Neurol; 2024 Jan; 23(1):46-59. PubMed ID: 38101902
[TBL] [Abstract][Full Text] [Related]
12. A history of stroke/transient ischemic attack indicates high risks of cardiovascular event and hemorrhagic stroke in patients with coronary artery disease.
Ducrocq G; Amarenco P; Labreuche J; Alberts MJ; Mas JL; Ohman EM; Goto S; Lavallée P; Bhatt DL; Steg PG
Circulation; 2013 Feb; 127(6):730-8. PubMed ID: 23277306
[TBL] [Abstract][Full Text] [Related]
13. Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome.
Gibson CM; Mega JL; Burton P; Goto S; Verheugt F; Bode C; Plotnikov A; Sun X; Cook-Bruns N; Braunwald E
Am Heart J; 2011 May; 161(5):815-821.e6. PubMed ID: 21570509
[TBL] [Abstract][Full Text] [Related]
14. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial.
Bousser MG; Amarenco P; Chamorro A; Fisher M; Ford I; Fox KM; Hennerici MG; Mattle HP; Rothwell PM; de Cordoüe A; Fratacci MD;
Lancet; 2011 Jun; 377(9782):2013-22. PubMed ID: 21616527
[TBL] [Abstract][Full Text] [Related]
15. Potential missed opportunities to prevent ischaemic stroke: prospective multicentre cohort study of atrial fibrillation-associated ischaemic stroke and TIA.
Wilson D; Ambler G; Shakeshaft C; Banerjee G; Charidimou A; Seiffge D; White M; Cohen H; Yousry T; Salman R AS; Lip GYH; Muir K; Brown MM; Jäger HR; Werring DJ;
BMJ Open; 2019 Jul; 9(7):e028387. PubMed ID: 31345970
[TBL] [Abstract][Full Text] [Related]
16. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation.
Camm AJ; Amarenco P; Haas S; Hess S; Kirchhof P; Kuhls S; van Eickels M; Turpie AG;
Eur Heart J; 2016 Apr; 37(14):1145-53. PubMed ID: 26330425
[TBL] [Abstract][Full Text] [Related]
17. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
De Schryver EL; Algra A; van Gijn J
Cochrane Database Syst Rev; 2003; (1):CD001820. PubMed ID: 12535415
[TBL] [Abstract][Full Text] [Related]
18. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group.
Lancet; 1993 Nov; 342(8882):1255-62. PubMed ID: 7901582
[TBL] [Abstract][Full Text] [Related]
19. Warfarin and aspirin in patients with heart failure and sinus rhythm.
Homma S; Thompson JL; Pullicino PM; Levin B; Freudenberger RS; Teerlink JR; Ammon SE; Graham S; Sacco RL; Mann DL; Mohr JP; Massie BM; Labovitz AJ; Anker SD; Lok DJ; Ponikowski P; Estol CJ; Lip GY; Di Tullio MR; Sanford AR; Mejia V; Gabriel AP; del Valle ML; Buchsbaum R;
N Engl J Med; 2012 May; 366(20):1859-69. PubMed ID: 22551105
[TBL] [Abstract][Full Text] [Related]
20. Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failure.
Sandhu RK; Hohnloser SH; Pfeffer MA; Yuan F; Hart RG; Yusuf S; Connolly SJ; McAlister FA; Healey JS
Stroke; 2015 Mar; 46(3):667-72. PubMed ID: 25628308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
